Shots: Health Canada has approved Luxturna (voretigene neparvovec) as a one-time gene therapy for the treatment of adult & pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells Luxturna is designed to provide functioning copies of the RPE65 gene to act […]Read More
Shots: The approval is based on P-III trial, involving assesment of Luxturna vs control group patients, with inherited retinal disease (caused due to mutation in both copies of the RPE65 gene and sufficient viable retinal cells) Results: Vision improvement recorded @ 30 days following treatment, @1yr. MLMT (multi-luminance mobility test) (1.6); 65% patients successfully navigate […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
